Meteora Capital’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-50,000
Closed -$14.9K – 495
2022
Q4
$14.9K Buy
+50,000
New +$10.1K ﹤0.01% 228

Meteora Capital's EBACW Position: Q1 2023 in Review

Meteora Capital sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q1 2023, closing a stake of 50,000 shares — an estimated $14.9K sold.

Meteora Capital first reported a position in EBACW in Q4 2022 and held it in 1 quarter. The position peaked at $14.9K in Q4 2022. 0 funds tracked by Wall St. Rank hold EBACW as of Q1 2023.

  • Meteora Capital reported no remaining European Biotech Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
  • Meteora Capital sold 50,000 European Biotech Acquisition Corp. Warrant shares in Q1 2023, an estimated $14.9K.
  • Meteora Capital first reported a position in European Biotech Acquisition Corp. Warrant in Q4 2022 and held it in 1 quarter.
  • Meteora Capital's European Biotech Acquisition Corp. Warrant position peaked at $14.9K in Q4 2022.
  • 0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q1 2023.

Based on Meteora Capital's 13F filing for Q1 2023, filed 15 May 2023.